Table 2.

Changes from baseline in patient’s assessment of pain intensity over 24 hours on Day 2 (measured before the morning dose on Day 3) among the intent-to-treat population.

Celecoxib, 50 mg bid, n = 100Celecoxib, 400/200 mg, n = 99Celecoxib, 800/400 mg, n = 96Indomethacin 50 mg tid, n = 102
Baseline
  n1009996102
  Mean (SD)3.03 (0.67)2.73 (0.62)2.84 (0.69)2.83 (0.76)
  Range2.0–4.02.0–4.02.0–4.02.0–4.0
Day 2 (change from baseline)
  n97969498
  Mean (SD)−1.14 (1.10)−1.23 (0.97)−1.51 (1.11)−1.62 (0.97)
  Range−4.0 to 1.0−3.0 to 1.0−4.0 to 1.0−3.0 to 1.0
Vs celecoxib 50 mg bid
  LS mean difference (SE)−0.24 (0.14)−0.46 (0.14)
  95% CI−0.52 to 0.04−0.74 to −0.18
  p0.09470.0014
Vs indomethacin 50 mg tid
  LS mean difference (SE)0.57 (0.14)0.33 (0.14)0.11 (0.14)
  95% CI0.29 to 0.840.05 to 0.60−0.17 to 0.39
  p< 0.00010.01960.4331
  • Bid: twice daily; LS: least squares; SE: standard error; tid: 3 times daily.